Trial · NCT00296322
Trial of Adjuvant Chemotherapy for Gastric Cancer
NCT00296322, Phase 3, Completed, Asan Medical Center; results first posted 2012-09-06
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Trial of Adjuvant Chemotherapy for Gastric Cancer. Trials, record NCT00296322. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00296322
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Trial of Adjuvant Chemotherapy for Gastric Cancer
- NCT number
- NCT00296322
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 528 participants, actual
- Lead sponsor
- Asan Medical Center
- Conditions
- Stomach Cancer
- Interventions
- cisplatin, mitomycin-C, doxifluridine
- First posted
- 2006-02-27
- Last updated
- 2020-01-18
- Results first posted
- 2012-09-06
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Relapse-free Survival | 3 years | |
| Secondary | Toxicity Profile (According to NCI CTC Version 2.0) | up to 1 year | Because safety profile in oncology study is evaluated for each toxicity, it is impossible to present the overall patient number. Instead, we presented the number of patients who declined study therapy due to adverse events or patient will. |
| Secondary | Overall Survival | 3 years |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Relapse-free Survival | 3 years | percentage of participants | NUMBER | |
| SECONDARY | Toxicity Profile (According to NCI CTC Version 2.0) | up to 1 year | participants | NUMBER | |
| SECONDARY | Overall Survival | 3 years | percentage of participants | NUMBER |
Source ClinicalTrials.gov
Results by group6
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Relapse-free Survival | Mitomycin and Short-term Fluoropyrimidine | 50.0 | 95% Confidence Interval 43.4 to 56.6 | percentage of participants | |
| Relapse-free Survival | iceMFP | 60.2 | 95% Confidence Interval 53.6 to 66.7 | percentage of participants | |
| Toxicity Profile (According to NCI CTC Version 2.0) | Mitomycin and Short-term Fluoropyrimidine | 13 | participants | ||
| Toxicity Profile (According to NCI CTC Version 2.0) | iceMFP | 30 | participants | ||
| Overall Survival | Mitomycin and Short-term Fluoropyrimidine | 59.6 | 95% Confidence Interval 52.9 to 66.3 | percentage of participants | |
| Overall Survival | iceMFP | 71.2 | 95% Confidence Interval 65.1 to 77.3 | percentage of participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Mitomycin and Short-term Fluoropyrimidine | 258 | |
| Overall Study | STARTED | iceMFP | 263 | |
| Overall Study | COMPLETED | Mitomycin and Short-term Fluoropyrimidine | 237 | |
| Overall Study | COMPLETED | iceMFP | 184 | |
| Overall Study | NOT COMPLETED | Mitomycin and Short-term Fluoropyrimidine | 21 | |
| Overall Study | NOT COMPLETED | iceMFP | 79 |
Source ClinicalTrials.gov
Adverse events32
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Neutropenia | Blood and lymphatic system disorders | Mitomycin and Short-term Fluoropyrimidine | 161 | 258 | |
| other | Neutropenia | Blood and lymphatic system disorders | iceMFP | 217 | 263 | |
| other | Anemia | Blood and lymphatic system disorders | Mitomycin and Short-term Fluoropyrimidine | 230 | 258 | |
| other | Anemia | Blood and lymphatic system disorders | iceMFP | 238 | 263 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Mitomycin and Short-term Fluoropyrimidine | 47 | 258 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | iceMFP | 62 | 263 | |
| other | Elevated AST or ALT | Hepatobiliary disorders | Mitomycin and Short-term Fluoropyrimidine | 82 | 258 | |
| other | Elevated AST or ALT | Hepatobiliary disorders | iceMFP | 60 | 263 | |
| other | Hyperbilirubinemia | Hepatobiliary disorders | Mitomycin and Short-term Fluoropyrimidine | 73 | 258 | |
| other | Hyperbilirubinemia | Hepatobiliary disorders | iceMFP | 83 | 263 |
1 to 10 of 32Source ClinicalTrials.gov
See all 32 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Mitomycin and Short-term Fluoropyrimidine | ||
| Total, all-cause mortality | iceMFP | ||
| Total, other adverse events | Mitomycin and Short-term Fluoropyrimidine | 230 | 258 |
| Total, other adverse events | iceMFP | 251 | 263 |
| Total, serious adverse events | Mitomycin and Short-term Fluoropyrimidine | 0 | 258 |
| Total, serious adverse events | iceMFP | 0 | 263 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Mitomycin and Short-term Fluoropyrimidine vs iceMFP: Toxicity Profile (According to NCI CTC Version 2.0) | Trial comparisons |
| Mitomycin and Short-term Fluoropyrimidine vs iceMFP: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00296322
GET https://conductscience.org/api/trials/v1/NCT00296322/events?page=2